Search

Researchers at Federal University Sao Joao del Rei in Divinopolis, Brazil, conducted a study on the interactions between phytomedicines containing Valeriana officinalis and Piper methysticum and conventional drugs. The study found that these phytomedicines inhibited the intestinal metabolism of midazolam in rats, leading to increased plasma concentration and area under the plasma concentration curve. However, the phytomedicines did not significantly affect the uptake of fexofenadine, except for kava-kava, which increased its uptake. The study suggests that these phytomedicines may have potential implications for drug interactions. [Extracted from the article]

This document provides information about a Phase 1 clinical trial for a drug called LY4100511. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of LY4100511 when taken alone or in combination with other drugs in healthy participants. Specifically, the trial will assess the potential drug-drug interactions of LY4100511 on certain substrates. The primary outcome measures of the trial include the pharmacokinetic parameters of midazolam and repaglinide in the absence or presence of LY4100511. The trial is being conducted by DICE Therapeutics, Inc., a subsidiary of Eli Lilly and Company, and is expected to be completed by October 2024. [Extracted from the article]

A recent report from Massachusetts General Hospital discusses the interaction effects of letermovir and tacrolimus in hematopoietic cell transplantation recipients. Letermovir is an approved drug for preventing cytomegalovirus infection in these recipients, and the study found that its coadministration with tacrolimus, a moderate cytochrome P450 3A4 inhibitor, led to a significant increase in tacrolimus levels. However, the dosage of tacrolimus needed to be reduced in patients receiving both drugs. The researchers recommend frequent monitoring of tacrolimus levels and considering a reduction in dosage when starting letermovir. [Extracted from the article]

A clinical trial, NCT06495164, is currently underway to investigate the use and effects of Palbociclib, an oral CDK4/6 inhibitor, in patients with hormone receptor-positive (HR+)/Human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). The trial aims to assess the real-life use and clinical impact of Palbociclib compared to hormonal therapy, as well as the duration of treatment with different CDK4/6 inhibitors and their potential impact on the need for chemotherapy. The trial will utilize de-identified data from medical records in routine clinical practice. Additionally, this document provides information about a separate clinical trial involving the CDK4/6 inhibitors Ribociclib, Abemaciclib, and Palbociclib, which are used in the treatment of metastatic breast cancer. The trial, sponsored by Pfizer, is currently active but not recruiting new participants and has enrolled 5087 patients. Its objective is to evaluate the effectiveness of different treatment regimens involving these drugs in combination with aromatase inhibitors. To be eligible for the trial, participants must be 18 years or older at the time of diagnosis and have confirmed HR+/HER2- metastatic breast cancer. The study is being conducted in the United States. [Extracted from the article]

A study conducted by researchers at the University of Florida explores the pharmacokinetics of carbamazepine (CBZ), a commonly prescribed drug for epilepsy. The study aims to investigate the mechanisms behind CBZ's nonlinear pharmacokinetics and its potential to induce the metabolism of other drugs. The researchers developed a physiologically based pharmacokinetic model of CBZ and its active metabolite and used it to predict drug-drug interactions with victim drugs metabolized by CYP3A4 and CYP2C9 enzymes. The study concludes that CBZ's nonlinear pharmacokinetics can be attributed to its nonlinear metabolism caused by autoinduction and nonlinear absorption due to poor solubility. The model developed in this study can help understand the potential for drug-drug interactions when CBZ serves as an inducer of CYP3A4 and CYP2C9 enzymes. [Extracted from the article]

A recent report from the University of Chicago discusses the potential use of lasofoxifene as a treatment for aromatase inhibitor-resistant ER-positive breast cancer. The study found that lasofoxifene, either alone or in combination with palbociclib, showed antitumor activity in a xenograft model of ER+ metastatic breast cancer. The research suggests that lasofoxifene, with or without a CDK4/6 inhibitor, may be beneficial for patients with ER-low and HER2-positive, AI-resistant breast cancer, regardless of ESR1 mutations. Further research is needed to explore the potential of lasofoxifene as a treatment option. [Extracted from the article]

A patent has been issued to Agios Pharmaceuticals Inc. for their therapy using mitapivat and modulators of cytochrome P450. Mitapivat is an allosteric activator of pyruvate kinase R (PKR) and is currently being studied in clinical trials for the treatment of pyruvate kinase deficiency (PKD), hemolytic anemia, and thalassemia. The patent describes methods of treating these conditions by administering mitapivat along with inhibitors or inducers of cytochrome P450 3A4/5 (CYP3A4/5) or p-glycoprotein. This research provides potential treatment options for individuals with these hematologic diseases. [Extracted from the article]

A study conducted by Pfizer examined the effects of the ketohexokinase inhibitor PF-06835919 on the induction of cytochrome P450 3A4 (CYP3A4) in the human body. The study found that PF-06835919 had minimal effect on the pharmacokinetics of midazolam, suggesting that it did not induce CYP3A4. This conclusion was supported by proteomic and activity analysis. The study highlights the use of an oral CYP3A probe and plasma-derived small extracellular vesicles to assess the induction potential of a drug candidate. [Extracted from the article]